clenbuterol

Indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Treat at effective dose for 30 days. At the end of the 30-day treatment period, drug should be withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extra label use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Ventipulmin® Syrup

VENTIPULMIN Syrup (clenbuterol hydrochloride) is indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Ventipulmin® Syrup (clenbuterol HCl)

VENTIPULMIN Syrup antagonizes the effects of prostaglandin F2 α and oxytocin. VENTIPULMIN Syrup should not be used in pregnant mares near term. Because tachycardia may occur, VENTIPULMIN Syrup should not be used in horses suspected of having cardiovascular impairment.

Ventipulmin® Syrup (clenbuterol HCl)

Not for use in humans. Do not use in horses intended for human consumption. Keep out of reach of children. In case of accidental ingestion, contact a physician immediately. Ingestion of VENTIPULMIN Syrup may cause undesirable reactions. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Ventipulmin® Syrup (clenbuterol HCl)

The effect on reproduction in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended.

Ventipulmin® Syrup (clenbuterol HCl)

Mild sweating, muscle tremor, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment. May cause elevated creatine kinase (CK) serum levels. Ataxia was observed in 3 out of 239 horses (1.3%) in clinical studies. To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

Ventipulmin® Syrup (clenbuterol HCl)

Administer orally twice a day. Initial dose is 0.5 milliliter per 100 pounds body weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2.0 milliliters per 100 pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, horse is nonresponder to clenbuterol and treatment should be discontinued.

Oral

Treat at effective dose for 30 days. At the end of the 30-day treatment period, drug should be withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extra label use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Ventipulmin® Syrup

Initial dosage: administer 0.5 mL/100 lbs (0.8 mcg/kg) for 3 days (6 treatments); If no improvement, administer 1.0 mL/100 lbs (1.6 mcg/kg) for 3 days (6 treatments); If no improvement, administer 1.5 mL/100 lbs (2.4 mcg/kg) for 3 days (6 treatments); If no improvement, administer 2.0 mL/100 lbs (3.2 mcg/kg) for 3 days (6 treatments); If no improvement, horse is non-responsive to clenbuterol and treatment should be discontinued. Recommended duration of treatment at effective dose is 30 days. At the end of this 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, the 30-day treatment regimen may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated.

ORAL

Ventipulmin® Syrup (clenbuterol HCl)

Lbs. Body Weight mL/treatment at 0.5 mL/100# (0.8 mcg/kg) mL/treatment at 1.0 mL/100# (1.6 mcg/kg) mL/treatment at 1.5 mL/100# (2.4 mcg/kg) mL/treatment at 2.0 mL/100# (3.2 mcg/kg) 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0 7.5 9.0 10.5 12.0 13.5 15.0 16.5 18.0 19.5 21.0 22.5 24.0 25.5 27.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 34.0 36.0 Administer two treatments per day.

ORAL

Ventipulmin® Syrup (clenbuterol HCl)

Administer orally twice a day (b.i.d.). Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily.

ORAL

Ventipulmin® Syrup (clenbuterol HCl)